Personalis, Inc. (PSNL): A Bull Case Theory [Yahoo! Finance]
Personalis, Inc. (PSNL)
Last personalis, inc. earnings: 3/25 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Personalis, Inc.'s share was trading at $9.97 as of January 29th. PSNL's trailing P/E was 53.95 according to Yahoo Finance. Photo by National Cancer Institute on Unsplash Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. PSNL represents a compelling investment opportunity driven by its flagship NeXT Personal test, a blood-based assay capable of detecting cancer recurrence 12–18 months earlier than traditional imaging. This ultra-sensitive test tracks up to 1,800 tumor variants using whole-genome sequencing, offering dramatically higher detection rates compared to incumbents like Natera's Signatera. While NeXT Personal currently contributes less than 1% of PSNL's $85M revenue, adoption is strong, with over 600 oncologists using the test and a 98% retention rate. The apparent disconnect in market perception arises from the test not yet being reimbursed by Medicare or private insurers; Personalis has b
Show less
Read more
Impact Snapshot
Event Time:
PSNL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PSNL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PSNL alerts
High impacting Personalis, Inc. news events
Weekly update
A roundup of the hottest topics
PSNL
News
- Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors [Yahoo! Finance]Yahoo! Finance
- Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid TumorsBusiness Wire
- Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceBusiness Wire
- Personalis (NASDAQ:PSNL) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Trackerâ„¢ [Yahoo! Finance]Yahoo! Finance
PSNL
Earnings
- 11/4/25 - Beat
PSNL
Sec Filings
- 1/29/26 - Form SCHEDULE
- 1/23/26 - Form 4
- 1/22/26 - Form 144
- PSNL's page on the SEC website